共 48 条
[1]
Aronne L.J., Thornton-Jones Z.D., New targets for obesity pharmacotherapy, Clin Pharmacol Ther, 81, pp. 748-752, (2007)
[2]
Berenson G.S., Srinivasan S.R., Emergence of obesity and cardiovascular risk for coronary artery disease: The Bogalusa Heart Study, Prev Cardiol, 4, pp. 116-121, (2001)
[3]
Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance, JAMA, 290, pp. 486-494, (2003)
[4]
Curioni C., Andre C., Rimonabant for overweight or obesity, Cochrane Database Syst Rev, 4, (2006)
[5]
Davidson M.H., Hauptman J., Digirolamo M., Foreyt J.P., Halsted C.H., Heber D., Heimburger D.C., Lucas C.P., Robbins D.C., Chung J., Heymsfield S.B., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial, JAMA, 281, pp. 235-242, (1999)
[6]
Deedwania P.C., Gupta R., Management issues in the metabolic syndrome, J Assoc Physicians India, 54, pp. 797-810, (2006)
[7]
Despres J.P., Golay A., Sjostrom L., Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia, N Engl J Med, 353, pp. 2121-2134, (2005)
[8]
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, pp. 393-403, (2002)
[9]
Ditschuneit H.H., Fletchner-Mors M., Johnson T.D., Adler G., Metabolic and weight-loss effects of a long-term dietary intervention in obese patients, Am J Clin Nutr, 69, pp. 198-204, (1999)
[10]
Douketis J.D., MacIe C., Thabane L., Williamson D.F., Systematic review of long-term weight loss studies in obese adults: Clinical significance and applicability to clinical practice, Int J Obes (Lond), 29, pp. 1153-1167, (2005)